Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low versus high dose radioactive iodine in differentiated thyroid cancer
IRCT138706171100N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of iodine-131 in well-differentiated thyroid cancer (WDTC), sponsored by Tehran University of Medical Sciences. Started Jun 2005; status: completed.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on IRCT138706171100N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138706171100N2.